$0.76 +0.00 (0.38%)

AEON Biopharma, Inc. (AEON)

AEON Biopharma, Inc. is a biotechnology company focused on developing targeted therapies for neurological and neurodegenerative disorders. The company aims to advance innovative treatments through rigorous research and clinical development, primarily targeting unmet medical needs in areas such as multiple sclerosis, stroke, and other brain-related conditions.

🚫 AEON Biopharma, Inc. does not pay dividends

Company News

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering
Benzinga • Globe Newswire • January 7, 2025

AEON Biopharma, a clinical-stage biopharmaceutical company, announced the closing of a $20 million public offering. The company plans to use the proceeds for general corporate purposes and working capital.

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
GlobeNewswire Inc. • N/A • January 4, 2025

AEON Biopharma, a clinical-stage biopharmaceutical company, announced a public offering of shares and warrants to raise funds for general corporate and working capital needs.

Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
Zacks Investment Research • Zacks Equity Research • May 29, 2024

AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.